NASDAQ · PFE
Healthcare · Drug Manufacturers - General
$28.37
Up+$0.85 (+2.98%)
Updated Oct 14, 2026, 4:17 PM
SID Score
7.5/10
Composite research score
Smart Money
63/100
Neutral
Price performance · PFE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
PFE closed at $28.37 after 21 trading sessions, up 2.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $28.61 | $28.61 | $28.13 | $28.37 | 26.84M |
| Oct 12, 2026 | $28.42 | $28.495 | $28.28 | $28.40 | 18.56M |
| Oct 9, 2026 | $27.61 | $28.285 | $27.59 | $28.28 | 23.2M |
| Oct 8, 2026 | $27.90 | $28.00 | $27.475 | $27.82 | 44.43M |
| Oct 7, 2026 | $27.62 | $28.17 | $27.55 | $28.00 | 31.23M |
| Oct 6, 2026 | $27.48 | $27.71 | $27.20 | $27.50 | 24.07M |
| Oct 5, 2026 | $27.65 | $27.72 | $27.12 | $27.41 | 33.01M |
| Oct 2, 2026 | $28.145 | $28.16 | $27.44 | $27.80 | 35.01M |
| Oct 1, 2026 | $28.445 | $28.585 | $28.075 | $28.12 | 30.49M |
| Sep 30, 2026 | $28.79 | $28.945 | $28.52 | $28.52 | 33.64M |
| Sep 29, 2026 | $28.60 | $28.76 | $28.26 | $28.72 | 33.31M |
| Sep 28, 2026 | $28.62 | $28.87 | $28.39 | $28.72 | 24.95M |
| Sep 25, 2026 | $28.45 | $28.69 | $28.17 | $28.67 | 27.76M |
| Sep 24, 2026 | $28.20 | $28.85 | $28.20 | $28.41 | 34.77M |
| Sep 23, 2026 | $27.96 | $28.23 | $27.84 | $28.18 | 33.81M |
| Sep 22, 2026 | $27.74 | $28.00 | $27.49 | $27.93 | 26.67M |
| Sep 21, 2026 | $27.65 | $27.92 | $27.53 | $27.74 | 28.78M |
| Sep 18, 2026 | $27.64 | $27.66 | $27.34 | $27.66 | 75.59M |
| Sep 17, 2026 | $27.62 | $27.81 | $27.55 | $27.64 | 29.01M |
| Sep 16, 2026 | $27.64 | $27.69 | $27.36 | $27.46 | 26.05M |
| Sep 15, 2026 | $27.615 | $27.66 | $27.245 | $27.55 | 40.44M |
The latest Smart Investors Daily articles mentioning PFE.
Company
Market Activity
Research & News
PFE research
Company profile and research snapshot.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Neutral | — |
| Oct 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Oct 6, 2026 | Scotiabank | Sector Outperform | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 9, 2026
Pfizer Inc. (NYSE:PFE) is up 11.4% year-to-date and leads to a classic value-versus-risk setup. The stock’s forward price-to-earnings multiple appears attractive, along with its healthy operating margin, and strong cash flow generation capacity. However, revenue growth remains sluggish, and the company’s thin bottom-line margin and low return on equity add to investor concerns. It explains […]
Yahoo · Oct 9, 2026
Pfizer recently received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy, expanding its use into the frontline metastatic setting. This decision is important because it moves TUKYSA into an earlier phase of care for a broader patient group, reinforcing Pfizer’s growing emphasis on targeted...
Yahoo · Oct 2, 2026
Runaway demand for AI data centers, highlighted by Nvidia’s US$5.7t market cap milestone, shows how quickly capital is chasing tools that can crunch medical data, scan images, and support virtual care at global scale. That same engine is starting to reshape healthcare. Missing the early phase may mean missing where a lot of value could potentially accrue. This article breaks down three AI healthcare stocks from the screener that are worth watching. The three stocks covered below are only a...
Yahoo · Oct 2, 2026
Key Stats for Pfizer StockCurrent Price: $28. 12Street Target (Mean): ~$29Next Earnings: November 3, 2026What Happened?Florida’s attorney general sued Pfizer (PFE:NYSE) and CEO Albert Bourla on Thursday, October 1, alleging the company misled consumers about its COVID-19 vaccine.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PFE.
